Author: Vijayan, Veena; Mohapatra, Adityanarayan; Uthaman, Saji; Park, In-Kyu
Title: Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials Document date: 2019_10_14
ID: 1d3xthbh_12
Snippet: VLPs are molecules that resemble the structure of viruses without viral genetic material. These self-assembling NPs that lack infectious nucleic acid are formed by the self-assembly of biocompatible capsid proteins. They are ideal nanovaccine systems, as they have the innate viral structure, which can interact with the immune system without any threat of causing infections [69, 70] . These VLPs can act as vaccines have nano-size and a repetitive .....
Document: VLPs are molecules that resemble the structure of viruses without viral genetic material. These self-assembling NPs that lack infectious nucleic acid are formed by the self-assembly of biocompatible capsid proteins. They are ideal nanovaccine systems, as they have the innate viral structure, which can interact with the immune system without any threat of causing infections [69, 70] . These VLPs can act as vaccines have nano-size and a repetitive structural order, and could induce an immune response in the absence of an adjuvant [71] . VLPs assemble without encapsulating any viral RNA, and hence they are noninfectious and nonreplicating, as the genes coded for viral integrase are deleted before expression. This prevents packed genome integration into the host cell, as well as the recombination of the live or defective virus. The first VLP vaccine was developed against the hepatitis B virus, which was later commercialized in 1986 [72] . VLP vaccines against hepatitis E and the human papillomavirus have been used in human since 2006 [73, 74] .
Search related documents:
Co phrase search for related documents- capsid protein and host cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- capsid protein and human papillomavirus: 1, 2, 3, 4, 5, 6, 7, 8
- capsid protein and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- capsid protein and immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- capsid protein and infectious nucleic acid: 1
- capsid protein and nucleic acid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- capsid protein and self assemble: 1, 2, 3, 4, 5
- capsid protein and viral genetic material: 1, 2, 3
- capsid protein and viral rna: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46
- capsid protein and viral rna encapsulate: 1, 2
- capsid protein and viral structure: 1, 2, 3, 4, 5, 6, 7, 8, 9
- capsid protein and virus structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- capsid protein and VLP vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9
- defective live virus and genome integration: 1
- defective live virus and host cell: 1
- defective live virus and host cell genome integration: 1
- defective live virus and human papillomavirus: 1
- defective live virus and VLP vaccine: 1
- defective live virus recombination and genome integration: 1
Co phrase search for related documents, hyperlinks ordered by date